Research programme: central nervous system therapeutics - Astellas Pharma/Icagen

Drug Profile

Research programme: central nervous system therapeutics - Astellas Pharma/Icagen

Latest Information Update: 24 Feb 2009

Price : $50

At a glance

  • Originator Icagen
  • Developer Astellas Pharma; Icagen
  • Class Small molecules
  • Mechanism of Action Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Dementia; Memory disorders

Most Recent Events

  • 06 Nov 2008 Discontinued - Preclinical for Memory disorders in Japan (unspecified route)
  • 06 Nov 2008 Discontinued - Preclinical for Dementia in Japan (unspecified route)
  • 06 Nov 2008 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top